miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia

Alacam, Huseyin; Akgün, Şakir; Akça, Hakan; Öztürk, Önder; Kabukcu, Burge Basay; Herken, Hasan

doi:10.1016/j.psychres.2016.08.037

Cited by 42 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This miRNA has been identified as upregulated in plasma of schizophrenia patients [ 171 ] and in serum of ASD patients [ 189 ], but other studies show it is decreased in serum of schizophrenia patients [ 187 ] or do not found a significant association [ 172 ]. Also, miR-195 levels are increased in plasma of schizophrenia patients resistant to treatment and decreased in patients responsive to treatment when compared with health donors [ 210 ] Within the brain, expression of this miRNAs is more associated with neurons rather than with glial cells [ 211 ]. Similarly to miR-30a, miR-195 directly targets BDNF [ 202 ].…”

Section: Clinical Research: Inflammatory Cells and Biomarkers In Asd mentioning

confidence: 99%

Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations

Prata

Santos

Almeida

et al. 2017

J Neuroinflammation

103

View full text Add to dashboard Cite

In recent years, evidence supporting a link between inflammation and neuropsychiatric disorders has been mounting. Autism spectrum disorders (ASD) and schizophrenia share some clinical similarities which we hypothesize might reflect the same biological basis, namely, in terms of inflammation. However, the diagnosis of ASD and schizophrenia relies solely on clinical symptoms, and to date, there is no clinically useful biomarker to diagnose or monitor the course of such illnesses. The focus of this review is the central role that inflammation plays in ASD and schizophrenia. It spans from pre-clinical animal models to clinical research and excludes in vitro studies. Four major areas are covered: (1) microglia, the inflammatory brain resident myeloid cells, (2) biomarkers, including circulating cytokines, oxidative stress markers, and microRNA players, known to influence cellular processes at brain and immune levels, (3) effect of anti-psychotics on biomarkers and other predictors of response, and (4) impact of gender on response to immune activation, biomarkers, and response to anti-psychotic treatments.

show abstract

Section: Clinical Research: Inflammatory Cells and Biomarkers In Asd mentioning

confidence: 99%

Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations

Prata

Santos

Almeida

et al. 2017

J Neuroinflammation

103

View full text Add to dashboard Cite

show abstract

“…27 miR-181b is significantly increased in the treatment-responsive group of schizophrenia, suggesting that it may act as a monitoring index reflecting the response to schizophrenia treatment. 28 This study found that circRNA15994-13 may influence the development of SGA, and further mechanistic research and validation of this regulatory pathway in the later stage should be performed.…”

Section: Discussionmentioning

confidence: 73%

“…n = 10 in each group. 28 This study found that circRNA15994-13 may influence the development of SGA, and further mechanistic research and validation of this regulatory pathway in the later stage should be performed. ***P < .001 diseases, and placental-derived diseases.…”

Section: Discussionmentioning

confidence: 76%

Differentially expressed circular RNAs in maternal and neonatal umbilical cord plasma from SGA compared with AGA

Wang

Dang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Small for gestational age (SGA) has a high risk of mortality and morbidity and is common in obstetrics. To date, no effective prediction and treatment tools are available. Acting as microRNA (miRNA) sponges and disease biomarkers are clear functions of circular RNAs (circRNAs). However, it is still unknown what role circRNAs act in SGA. To explore the role of circRNAs in SGA, circRNA expression patterns of the umbilical cord and maternal plasma in SGA was assessed. We first evaluated circRNAs in umbilical cord blood of the SGA and appropriate for gestational age (AGA) groups by microarray sequencing. In total, 170 340 circRNAs were sequenced, and 144 circRNAs were significantly upregulated while 977 were markedly downregulated. Has_circRNA15994‐13, has_circ_0001359, and has_circ_0001360 were abundant and differentially expressed between the SGA and AGA groups, and confirmed in the umbilical cord and maternal blood specimens by reverse transcription polymerase chain reaction. By combining miRNA microarray data of the SGA placenta tissue in NCBI, it was found that two miRNAs were both hsa_circRNA15994‐13 targets and differentially expressed, including hsa‐miR‐3619‐5p and hsa‐miR‐4741. Further KEEG analysis revealed that the most significant pathway enriched by hsa‐miR‐3619‐5p was Wnt signaling that is closely related to SGA; meanwhile, previous reports demonstrated that hsa‐miR‐3619‐5p directly binds to β‐catenin to accommodate the Wnt/β‐catenin pathway, whereby the suggestive hsa_circRNA15994‐13 → hsa‐miR‐3619‐5p → β‐catenin signaling pathway may play an important part in SGA.

show abstract

“…As with attempts to identify biomarkers for diagnosing schizophrenia, attempts to identify non-coding RNA biomarkers of treatment resistance have proposed both common and differing sets of RNA biomarkers. Alacam et al showed that plasma levels of miR-181B, miR-195, and miR-301A are increased in treatment-resistant patients and decreased in treatment-responsive patients compared to controls [ 136 ]. Another study also identified plasma levels of miR-181B as a potential biomarker of symptom improvements and treatment response, but suggested this mRNA can most reliably predict treatment resistance, as part of a combined biomarker panel of miRNA that included miR-30e, miR-132, and miR-432 [ 131 ].…”

Section: Non-coding Rnas As Peripheral Biomarkers Of Schizophreniamentioning

confidence: 99%

Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia

Gibbons

Udawela

Dean

2018

ncRNA

View full text Add to dashboard Cite

Schizophrenia is associated with diverse changes in the brain’s transcriptome and proteome. Underlying these changes is the complex dysregulation of gene expression and protein production that varies both spatially across brain regions and temporally with the progression of the illness. The growing body of literature showing changes in non-coding RNA in individuals with schizophrenia offers new insights into the mechanisms causing this dysregulation. A large number of studies have reported that the expression of microRNA (miRNA) is altered in the brains of individuals with schizophrenia. This evidence is complemented by findings that single nucleotide polymorphisms (SNPs) in miRNA host gene sequences can confer an increased risk of developing the disorder. Additionally, recent evidence suggests the expression of other non-coding RNAs, such as small nucleolar RNA and long non-coding RNA, may also be affected in schizophrenia. Understanding how these changes in non-coding RNAs contribute to the development and progression of schizophrenia offers potential avenues for the better treatment and diagnosis of the disorder. This review will focus on the evidence supporting the involvement of non-coding RNA in schizophrenia and its therapeutic potential.

show abstract

miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia

Cited by 42 publications

References 34 publications

Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations

Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations

Differentially expressed circular RNAs in maternal and neonatal umbilical cord plasma from SGA compared with AGA

Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia

Contact Info

Product

Resources

About